Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Stocksavior14 Jan. 14 at 5:17 PM

$PPBT I bet NT219 is basically on the shelf, that’s why they are now going to manipulate and milk retail by promoting their newer preclinical drugs🤣🤣🤣

0 · Reply

StocHolliday Jan. 14 at 2:57 PM

$PPBT the line about CAPTN-3 being clearly communicated as their lead program is such a brazen lie. I have lost all hope in the intentions of this company. It is genuinely a grift. If only I was racist - I could have avoided this calamity.

0 · Reply

Smittysixty Jan. 14 at 2:42 PM

$PPBT Trade Winds Capital held 100 shares at the end of Q3… and sold 90. That’s literally a sub‑$90 transaction — yet the trolls are parading it around like it’s some massive institutional signal. That level of desperation is honestly hilarious. The real players won’t show their updated positions until mid‑February. That’s when we’ll see who actually added, who accumulated quietly, and who’s positioning for 2026. Until then, trolls will keep trying to distract from the facts because they’ve got nothing else to work with.

1 · Reply

Purplepayday Jan. 14 at 1:53 PM

$PPBT So, i guess that we don’t need the data of the 100mg dose for NT219, that Smitty says that we have been missing for more than 600 days….. Because it have become irrelevant now that they only dose with 75mg 🧐

0 · Reply

Purplepayday Jan. 14 at 1:26 PM

$PPBT

0 · Reply

Stocksavior14 Jan. 14 at 12:42 PM

$PPBT not all those claims are correct? Ok tell me which one? Cause Israels innovation has factually led to everything I mentioned. Not to mention A LOT of drugs that “Muslims” use, were invented by Israel LOL just because this seems to be a scam company doesn’t mean all drugs were Also, it’s like you lunatics are just getting dumber and dumber…Shameless annexation of land and killing 1000s of innocence?? The Muslims launch rockets into Israel not caring who or what it hits, but you idiots say nothing…The Muslims declared war on Israel when they invaded & killed over 2000 people in Israel, MOSTLY innocent people, such as the ones attending a festival…& you idiots say nothing about that. Israel has NOT once taken land from Muslims unprovoked… BOTH times was AFTER Muslims decided to attack Israel… in the 1940s and then 1960s (IN DEFENSE). If they didn’t want to lose land, they shouldn’t have attacked. Israel actually gave land BACK after. NAME ONE MAJOR WAR WHERE INNOCENTS DIDNT DIE?

1 · Reply

JuggernautRaider Jan. 14 at 2:03 AM

$NUVB $9 is my floor and I’ve been buying since $1.50 (adding more now). Given how many undervalued assets there are - CM24 from $PPBT or even $TOVX to mind - then maybe I should email Doctor Hung so we get a real oncology leader to bring a game-changing pancreatic cancer asset to market… 🧐 Does anyone have Hung’s email by chance? We need an oncology leader like him running more programs at Nuvation. 🧠

0 · Reply

Smittysixty Jan. 14 at 1:09 AM

$PPBT NT219 dose change ≠ failure. Let’s clear this up: Moving from 100mg to 75mg in NT219’s Phase 2 isn’t a retreat — it’s a refinement. • RP2D was set at 100mg/kg after clean Phase 1 data • But 50mg/kg already showed confirmed PRs + biomarker correlation • So 75mg/kg is a strategic middle ground: 1)Maintains efficacy 2)Reduces exposure 3)Improves tolerability 4) Still above the threshold where responses were observed This is how dose optimization works in oncology.!You don’t need max dose if lower doses are already effective — especially with combo regimens. Calling it a failure is either uninformed or intentionally misleading. The science says otherwise.

0 · Reply

Shullders Jan. 14 at 12:58 AM

$PPBT good job on shaming these pigs Anthony and Steven!

0 · Reply

trucksolutions Jan. 14 at 12:00 AM

$PPBT shareholders burned to the ground.. lost a big money

0 · Reply

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Nov 14, 2025, 8:00 AM EST - 2 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:33 AM EDT - 2 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 20, 2025, 4:00 PM EDT - 3 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 5, 2025, 4:00 PM EDT - 4 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Aug 27, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 6 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 7 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 8 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 8 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 9 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 11 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 11 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Stocksavior14 Jan. 14 at 5:17 PM

$PPBT I bet NT219 is basically on the shelf, that’s why they are now going to manipulate and milk retail by promoting their newer preclinical drugs🤣🤣🤣

0 · Reply

StocHolliday Jan. 14 at 2:57 PM

0 · Reply

Smittysixty Jan. 14 at 2:42 PM

1 · Reply

Purplepayday Jan. 14 at 1:53 PM

0 · Reply

Purplepayday Jan. 14 at 1:26 PM

$PPBT

0 · Reply

Stocksavior14 Jan. 14 at 12:42 PM

1 · Reply

JuggernautRaider Jan. 14 at 2:03 AM

0 · Reply

Smittysixty Jan. 14 at 1:09 AM

0 · Reply

Shullders Jan. 14 at 12:58 AM

$PPBT good job on shaming these pigs Anthony and Steven!

0 · Reply

trucksolutions Jan. 14 at 12:00 AM

$PPBT shareholders burned to the ground.. lost a big money

0 · Reply

Stocksavior14 Jan. 13 at 11:43 PM

$PPBT I swear, you anti-Semite people really are some of the dumbest out there. Israel is the LARGEST producer of generic drugs in the world Babysense baby monitoring which millions world wide use was invented in Israel If anyone has ever used a USB flash drive, you can thank Israel. That mobile phone you use, you can thank Israel for that as they were the first to develop a mobile phone. If you ever instant messaged, you can thank Israel for that, they were the first to develop that. Farmers that use drip irrigation can thank Israel Cherry tomatoes that people love eating, you can thank Israel. AND THE LIST GOES ON… militarily stuff, agriculture, drugs, data encryption, etc etc

0 · Reply

hughjazz15 Jan. 13 at 10:57 PM

$PPBT rot in hell Gil

0 · Reply

trucksolutions Jan. 13 at 10:22 PM

$PPBT when the jews knew to make any sustainable and real product? Tell me if i'm wrong?!

0 · Reply

melissascrookedtooth Jan. 13 at 9:23 PM

$PPBT oh Gil tell me, tell me, tell me lies, tell me lies, tell me sweet little lies you can't even admit you got the dosing wrong for nt219 phase 2. cm24 is 14 months of inactivity after you tried 3 conference presentations of its data. and now you are calling pre-ind toxicology studies a derisking milestone... which you will have to pay a half million dollar milestone payment to immunorizon at the time of IND clearance. but yes, you are an achiever and can do no wrong in your mother eyes! her little boy ceo

2 · Reply

Smittysixty Jan. 13 at 8:41 PM

$PPBT Let me say it again. When a company elevates one program to “lead asset” status, it usually means the other programs are already deep in discussions behind the scenes. So yeah — NT219 and CM24 negotiations might be wrapped up or close to it, IMO. And now IM1240 becomes the centerpiece. You don’t start human trials in 2026 without funding or a partner lined up, which makes 2026 look very interesting. No surprise institutions are quietly building positions. I’m more than comfortable having averaged down to levels that match management/insider pricing. $10M cash on hand. $7M market cap. Trading below cash value 🤣 Call it what you want — to me it looks like a rare setup. And the trolls losing their minds trying to keep people away at these levels only confirms it.

0 · Reply

Smittysixty Jan. 13 at 8:35 PM

$PPBT You know you struck a nerve when the same old trolls suddenly turn into full‑time investigators, digging through my ancient posts like it’s their day job. Looks like something I noted in the corporate deck struck a nerve 🤔

0 · Reply

Stocksavior14 Jan. 13 at 6:11 PM

$PPBT hahahahah !!! So after 5 years of LYING, MISLEADING, convincing people to BLOCK anyone who disagrees, and all the SHIT TALK AND calling myself and others paid bashers, and he’s admitting this has been a shit show and that he’s going to be “cautious” LOL🤣🤣🤣 If the company had amazing data coming or anything really great, they wouldn’t have been diluting at rock bottom prices…. And they have handed their “friends” cheap shares and warrants because no matter how low or bad the stock price, they wanted to enable their buddies to all make money while RETAIL paid for all of it and suffered. Soon Smitty will be completely gone after destroying so many people.

0 · Reply

Stocksavior14 Jan. 13 at 6:08 PM

$PPBT big lesson for any new people to this app or stock trading, when you have people like Smitty and Dr. Him and YAMI…. Take everything they say with a grain of salt as they are probably terrible traders or paid pumpers…. Or in some cases paid bashers (but not the case in this stock, they were pumpers)

0 · Reply

Purplepayday Jan. 13 at 5:52 PM

$PPBT .. far more cautious 😂 And still misjudging 🙄

0 · Reply

StocHolliday Jan. 13 at 5:43 PM

$PPBT if anyone from management is reading this board, genuinely how do you feel anything but shame for your pathetic performance? What have you accomplished within the last five years that isn't comically irrelevant?

1 · Reply

Smittysixty Jan. 13 at 5:28 PM

$PPBT The new deck is a business development roadmap. Look at the structure: • CM24 → Partner‑ready • NT219 → Partner‑ready • IM1240 → Elevated to “lead asset” This is how companies sequence deals: Two assets prepared for monetization. One asset positioned as the next negotiation target. The January deck isn’t a “growth story.” It’s a transaction story. Multiple shots on goal. Each one framed for a different type of deal.

0 · Reply

Smittysixty Jan. 13 at 5:27 PM

$PPBT NT219 is being framed as a combo‑ready immunotherapy enhancer. The new deck pushes NT219 into the spotlight for combo potential. Key signals: • Phase 2 launched (pembro + cetuximab arms) • Predictive biomarkers identified (pIGF1R, pSTAT3) • Re‑sensitizes αPD1‑resistant tumors • Reprograms the TME (↑ NK/T cells, ↓ MDSCs) • $5B+ market in SCCHN • Also placed under “Partnership Opportunities” This is classic BD packaging: mechanism + biomarkers + market size + clean safety.

0 · Reply

Market Cap	8.74M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	44,003
Avg Vol	583,084
Day's Range	N/A - N/A
Shares Out	12.85M
Stochastic %K	35%
Beta	0.64
Analysts	Sell
Price Target	$34.00